A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
NCT06297590
Recruiting
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of two parts, A and B. Each enrolled participant in Part A will receive a single dose of LY3954068 or placebo (no active drug) given into the spinal fluid. Each participant in Part B will receive 2 dose... Read More
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
08/12/2025
Locations: K2 Medical Research, LLC, Maitland, Florida +9 locations
Conditions: Alzheimer Disease
Register for Updates
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
NCT06285643
Recruiting
The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.
Gender:
ALL
Ages:
Between 45 years and 75 years
Trial Updated:
08/12/2025
Locations: UCI Alpha Clinic (Neurology), Irvine, California +38 locations
Conditions: Parkinson Disease
Register for Updates
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588
Recruiting
The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (hereafter referred to as EGFR mutations or EGFR-mutated) or any of the follow genomic alterations: ALK gene rearrangements, ROS1 rearrangements, BRAF V600E mutations, NTRK gene fusions, MET exon 14 skipping mutations, RET rearrangements, or less common EGFR point m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: UCLA Hematology/Oncology - Santa Monica ( Site 0023), Los Angeles, California +189 locations
Conditions: Non-small Cell Lung Cancer (NSCLC)
Register for Updates
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
NCT06920901
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and immunogenicity of APG777 in adult participants with mild-to-moderate asthma. The duration of the study will be approximately 52 weeks (364 days) for each participant and will consist of a Screening Period, Treatment Period, and Follow-up Period.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/12/2025
Locations: Investigational Site, La Jolla, California +11 locations
Conditions: Asthma
Register for Updates
DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit
NCT06645236
Recruiting
To utilize the therascreen KRAS RGQ PCR Kit, as a screening test in Amgen's Phase 3 Clinical Study Protocol 20210081, in order to identify patients with mCRC KRAS G12C mutation positive tumors to be enrolled in the drug clinical trial. Results of the Phase 3 Amgen Study 20210081 will serve as the basis for establishing the clinical performance of the therascreen® KRAS RGQ PCR Kit as a companion diagnostic (CDx) for the identification of patients with metastatic colorectal cancer, who may benefit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: QIAGEN Gaithersburg, Inc, Manchester, Not set
Conditions: Metastatic Colorectal Cancer (mCRC)
Register for Updates
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478
Recruiting
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric cancer ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, prostate cancer, second-line gastric cancer, lung cancer, and breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: City of Hope, Duarte, California +74 locations
Conditions: Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer
Register for Updates
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846
Recruiting
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab vedotin is in adult participants with NSCLC who have previously been treated. Change in disease activity and adverse events will be assessed. Telisotuzum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: University of Alabama at Birmingham - Main /ID# 247074, Birmingham, Alabama +304 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
NCT04176198
Recruiting
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: University of Alabama, Birmingham, Alabama +77 locations
Conditions: Myelofibrosis
Register for Updates
Clinical Evaluation of a Paediatric Sleep Diagnosis Technology
NCT04031950
Recruiting
The objective of this project is to gather research data and subsequently evaluate algorithms to demonstrate clinical efficacy of a novel sleep apnoea detection system in the paediatric population. The Study will involve patients who will have been referred for diagnosis of sleep apnoea, and the ultimate aim will be to compare the output of a novel apnoea detection system against in -clinic polysomnography.
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
08/12/2025
Locations: Sheffield Children Hospital, Sheffield, Not set +1 locations
Conditions: Sleep Apnea
Register for Updates
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
NCT06428396
Recruiting
The purpose of this study is to assess the efficacy and safety of belzutifan (MK-6482) plus fulvestrant compared to everolimus plus endocrine therapy (ET) (investigator's choice of fulvestrant or exemestane) in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) unresectable metastatic breast cancer. There is no formal hypothesis testing in this study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: City of Hope - Phoenix ( Site 0006), Goodyear, Arizona +36 locations
Conditions: Metastatic Breast Cancer
Register for Updates
BELIDE: Better Living With Non-memory-led Dementia
NCT06241287
Recruiting
Around 48 million people worldwide 1 live with dementia, of whom 3.9 million start with symptoms before the age of 65 (young-onset dementia). Most of the people presenting with young-onset dementia and some people with later onset dementia develop non-memory led dementias such as the atypical forms of Alzheimer ́s disease (AD)or frontotemporal dementia (FTD). Despite the proven benefits of educational programmes and skill training for caregivers, families of people with non-memory led dementias... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: University College London, London, Not set
Conditions: Dementia
Register for Updates
A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
NCT06500702
Recruiting
This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD). The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, SAR442970, or rilzabrutinib compared with placebo in participants with primary FSGS or primary MCD aged 16 to 75 years. Study details for each participant include: The study duration... Read More
Gender:
ALL
Ages:
Between 16 years and 75 years
Trial Updated:
08/12/2025
Locations: Investigational Site Number: 8400007, Birmingham, Alabama +57 locations
Conditions: Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
Register for Updates